Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9619691rdf:typepubmed:Citationlld:pubmed
pubmed-article:9619691lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:9619691lifeskim:mentionsumls-concept:C0047911lld:lifeskim
pubmed-article:9619691lifeskim:mentionsumls-concept:C1881985lld:lifeskim
pubmed-article:9619691pubmed:issue2lld:pubmed
pubmed-article:9619691pubmed:dateCreated1998-7-17lld:pubmed
pubmed-article:9619691pubmed:abstractTextIn vitro, cytosolic human ketone reductases catalyse the stereospecific (i.e. >99%) formation of S(-) reduced haloperidol (RHP) from haloperidol (HP). Whether this situation is reflected in patients taking the drug is unknown. In this study in nine patients taking HP, only 73.2+/-18.2% of the RHP excreted in urine was the S(-) enantiomer. Thus, enzymes other than cytosolic ketone reductases must be responsible for the formation of the minor enantiomer.lld:pubmed
pubmed-article:9619691pubmed:languageenglld:pubmed
pubmed-article:9619691pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9619691pubmed:citationSubsetIMlld:pubmed
pubmed-article:9619691pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9619691pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9619691pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9619691pubmed:statusMEDLINElld:pubmed
pubmed-article:9619691pubmed:monthMaylld:pubmed
pubmed-article:9619691pubmed:issn0924-977Xlld:pubmed
pubmed-article:9619691pubmed:authorpubmed-author:PondS MSMlld:pubmed
pubmed-article:9619691pubmed:authorpubmed-author:McGrathJ JJJlld:pubmed
pubmed-article:9619691pubmed:authorpubmed-author:StedmanT JTJlld:pubmed
pubmed-article:9619691pubmed:authorpubmed-author:EylesD WDWlld:pubmed
pubmed-article:9619691pubmed:issnTypePrintlld:pubmed
pubmed-article:9619691pubmed:volume8lld:pubmed
pubmed-article:9619691pubmed:ownerNLMlld:pubmed
pubmed-article:9619691pubmed:authorsCompleteYlld:pubmed
pubmed-article:9619691pubmed:pagination127-9lld:pubmed
pubmed-article:9619691pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9619691pubmed:meshHeadingpubmed-meshheading:9619691-...lld:pubmed
pubmed-article:9619691pubmed:meshHeadingpubmed-meshheading:9619691-...lld:pubmed
pubmed-article:9619691pubmed:meshHeadingpubmed-meshheading:9619691-...lld:pubmed
pubmed-article:9619691pubmed:meshHeadingpubmed-meshheading:9619691-...lld:pubmed
pubmed-article:9619691pubmed:meshHeadingpubmed-meshheading:9619691-...lld:pubmed
pubmed-article:9619691pubmed:meshHeadingpubmed-meshheading:9619691-...lld:pubmed
pubmed-article:9619691pubmed:meshHeadingpubmed-meshheading:9619691-...lld:pubmed
pubmed-article:9619691pubmed:meshHeadingpubmed-meshheading:9619691-...lld:pubmed
pubmed-article:9619691pubmed:meshHeadingpubmed-meshheading:9619691-...lld:pubmed
pubmed-article:9619691pubmed:year1998lld:pubmed
pubmed-article:9619691pubmed:articleTitleChirality of reduced haloperidol in humans.lld:pubmed
pubmed-article:9619691pubmed:affiliationQueensland Centre for Schizophrenia Research, Wolston Park Hospital, Wacol, Brisbane, Australia.lld:pubmed
pubmed-article:9619691pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9619691pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:9619691pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed